Indianapolis, IN, United States of America

Tara Suzanne Umberger

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Eli Lilly and Company. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tara Suzanne Umberger. Retrieved from https://idiyas.com/inventor/tara-suzanne-umberger

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Tara Suzanne Umberger: Innovator in Oxyntomodulin Binding Molecules

Introduction

Tara Suzanne Umberger is an inventor based in Frankton, IN (US). She has made significant contributions to the field of biochemistry, particularly in the development of novel binding molecules related to oxyntomodulin. Her work focuses on the quantitation of this important polypeptide, which has implications for various medical applications.

Latest Patent Applications

Tara's latest patent application is titled "OXYNTOMODULIN BINDING MOLECULES, AND USES THEREOF." This application provides details on novel N- and C-terminal oxyntomodulin polypeptide binding molecules and their uses, including a method for quantitating oxyntomodulin. Although she currently holds no granted patents, her research is poised to contribute to advancements in the field.

Conclusion

Tara Suzanne Umberger is an innovative inventor whose work on oxyntomodulin binding molecules showcases her potential to impact biochemistry and medical research. Her latest patent application reflects her commitment to advancing scientific knowledge and applications in this area.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…